FY2025 EPS Estimates for Opthea Reduced by Leerink Partnrs

Opthea Limited (NASDAQ:OPT) – Research analysts at Leerink Partnrs cut their FY2025 earnings estimates for Opthea in a note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($1.62) per share for the year, down from their prior estimate of ($1.15). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.37) EPS.

Several other equities research analysts have also recently commented on OPT. Jefferies Financial Group reissued an “underperform” rating and issued a $1.00 target price (down from $8.00) on shares of Opthea in a research note on Tuesday. Oppenheimer lowered Opthea from an “outperform” rating to a “market perform” rating in a research report on Monday, March 24th. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a report on Tuesday, December 17th. HC Wainwright lowered shares of Opthea from a “buy” rating to a “neutral” rating and reduced their target price for the company from $12.00 to $2.00 in a research note on Tuesday. Finally, Leerink Partners downgraded shares of Opthea from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $12.00 to $1.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $1.33.

Opthea Price Performance

Shares of Opthea stock opened at $3.41 on Thursday. The firm has a 50 day simple moving average of $4.40 and a 200 day simple moving average of $4.07. Opthea has a fifty-two week low of $1.79 and a fifty-two week high of $6.30.

Institutional Investors Weigh In On Opthea

Hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC acquired a new position in Opthea in the 4th quarter worth $556,000. Jane Street Group LLC bought a new position in shares of Opthea during the 3rd quarter worth approximately $114,000. Citadel Advisors LLC acquired a new stake in shares of Opthea in the fourth quarter valued at approximately $79,000. Twin Lakes Capital Management LLC bought a new stake in shares of Opthea in the third quarter worth $81,000. Finally, OLD Mission Capital LLC acquired a new position in Opthea during the fourth quarter worth $42,000. Institutional investors and hedge funds own 55.95% of the company’s stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.